Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

DP _DETECTION: An outlier detection algorithm based on density of big data
Li, Xiaodi , Huang, Ming , Li, Dingcheng , Wang, Hongjun , Deng, Ping

Mayo Clinic

Data Science and Knowledge Engineering for Sensing Decision Support | July 31, 2018 | Volume: No volume available | Issue: No issue available | Pages: 534-544

10.1142/9789813273238_0069 Get It

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Rambau, Peter , Vierkant, Robert A. , Intermaggio, Maria P., Kelemen, Linda E. , Goodman, Marc T. , Herpel, Esther , Kommoss, Stefan , Jimenez‐Liñan, Mercedes , Menon, Usha , Polo, Susanna Hernando, Reis, Francisco José Cândido dos , Gayther, Simon A. , Sharma, Raghwa , Harnett, Paul R. , Hatfield, Emma, Andrade, Jurandyr Moreira de , Nelson, Gregg , Steed, Helen , Schildkraut, Joellen M. , Carney, Micheal E, Høgdall, Estrid , Whittemore, Alice S. , Widschwendter, Martin , Kennedy, Catherine J. , Armasu, Sebastian M. , Daley, Frances , Coulson, Penny , Jones, Michael E. , Anglesio, Michael S. , Chow, Christine , Fazio, Anna de , García‐Closas, Montserrat , Huzarski, Tomasz , Jensen, Allan , Lubiński, Jan , Oszurek, Oleg, Benı́tez, Javier , Mina, Fady , Staebler, Annette , Taran, Florin‐Andrei , Pasternak, J , Talhouk, Aline , Rossing, Mary Anne, Hendley, Joy , Group, AOCS, Fereday, Sián , Ness, Roberta B., Sieh, Weiva , El‐Bahrawy, Mona , Lester, Jenny , Sinn, Hans‐Peter , Fasching, Peter A. , Chang‐Claude, Jenny , Moysich, Kirsten B. , Bowtell, David D.L. , Luk, Hugh, Shah, Mitul , Jung, Audrey , Alsop, Jennifer , Thompson, Pamela J., Swerdlow, Anthony J. , Karpinskyj, Chloe , García, María J. , Deen, Susha, Palacios, José , Koziak, Jennifer M. , Goode, Ellen L. , Huntsman, David G. , Ramus, Susan J. , Köbel, Martin , DeFazio, Anna , Köbel, Martin , Ramus, Susan J , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Swerdlow, Anthony J , Moysich, Kirsten , Kennedy, Catherine J , Sinn, Peter , Widschwendter, Martin , Anglesio, Michael S , Jones, Michael E , Sieh, Weiva , García-Closas, Montserrat , Benitez, Javier , Høgdall, Estrid , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Fereday, Sian , Lubinski, Jan , Nelson, Gregg S , El-Bahrawy, Mona A , Harnett, Paul R , Steed, Helen , Goodman, Marc T , Pharoah, Paul D.P. , Karlan, Beth Y. , Gentry‐Maharaj, Aleksandra , Doherty, Jennifer A. , Larson, Melissa C. , Hatfield, Emma, Wang, Frances M. , Wang, Qin , Wang, Chen , Brucker, Sara Yvonne , Cybulski, Cezary , Harris, Holly R. , Hartkopf, Andreas D , Group, AOCS, Edwards, Todd , Modugno, Francesmary , Winham, Stacey J. , Kjær, Susanne K. , Gronwald, Jacek , Hernandez, Brenda Y. , Behrens, Sabine , Ghatage, Prafull , Alsop, Kathryn , García-Donás, Jesús , Cazorla, Alicia , Wilkens, Lynne R. , Berchuck, Andrew , Brenton, James D. , Cook, Linda S.

Mayo Clinic

The Journal of Pathology: Clinical Research | July 30, 2018 | Volume: 4 | Issue: 4 | Pages: 250-261

10.1002/cjp2.109 | PMID 30062862 Get It

AbstractWe aimed to validate the prognostic association of p16 expression in ovarian high‐grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical‐grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis‐associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while absence was associated with shorter OS in low‐grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype‐specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low‐grade serous carcinoma justifies CDK4 inhibition.
A droplet microfluidic platform for efficient enzymatic chromatin digestion enables robust determination of nucleosome positioning
Xu, Yi , Lee, Jeong‐Heon , Li, Zhaoyu , Wang, Liguo , Ördög, Tamás , Li, Zhaoyu , Lee, Jeong-Heon , Wang, Liguo , Bailey, Ryan C

Mayo Clinic

Lab on a Chip | July 26, 2018 | Volume: 18 | Issue: 17 | Pages: 2583-2592

10.1039/c8lc00599k | PMID 30046796 Get It

A microfluidic device was designed to efficiently fragment chromatin for downstream epigenetic assays.
Multicenter Laboratory Comparison of Iohexol Measurement
Schwartz, George J. , Wang, Hongyue , Erway, Brian, Seegmiller, Jesse C. , Bäck, Sten-Erik, Miller, W. Greg , Eckfeldt, John H., Nordin, Gunnar , Lieske, John C.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 5 | Pages: 711-724

10.1373/jalm.2017.024240 | PMID 31276084 Get It

Abstract Background Iohexol is used for measurement of kidney glomerular filtration rate (GFR). Until recently, there have not been available proficiency standards to assist in calibrating a laboratory's results. In view of a shift in calibration at the University of Rochester Medical Center (URMC) laboratory, serving as Central Biochemistry Laboratory for the CKiD study, we performed a multicentered laboratory comparison. Methods Two batches of 30 fortified sera and patient samples from serum or heparinized plasma were sent for duplicate analysis to URMC, University of Minnesota (UMN), Mayo Clinic, and University of Lund. Five proficiency testing materials from Equalis AB were also provided. Iohexol calibration was performed using dilutions of OmnipaqueTM 300 and concentrations measured by HPLC or LC-MS/MS (Mayo). Results The 2 batches sent to UMN and University of Lund agreed well. URMC calibration was 11%–13% lower, and Mayo was 4%–8% lower for fortified samples. URMC corrected calibration was 3%–8% higher for these samples. When measured values were adjusted for the results of the Equalis samples, all laboratories agreed within 1%–2% on all iohexol concentrations. Conclusions For 12 URMC calibrator lots from November 2006 to March 2016, the factor quantifying the underestimation of measured to true iohexol concentration was 0.89. If each concentration was divided by 0.89, the calculated GFRs would be reduced by 10%–11%. GFR results for CKiD were adjusted for this shift in calibration. Regular examination of iohexol proficiency testing materials, free exchange of samples among laboratories, and standardized dilution of the stock iohexol for calibration would help to bring more universal agreement to this assay.
Proton therapy patterns of care among pediatric and adult patients with CNS tumors
Hartsell, William F. , Badiyan, Shahed N. , Wang, Chiachien J., Rossi, Carl J., Kotecha, Rupesh , Vora, Sujay A., Vargas, Carlos , Larson, Gary, Halasz, Lia M. , Vora, Sujay, Tseng, Yolanda D. , Tsai, Henry K.

Mayo Clinic

Neuro-Oncology | July 23, 2018 | Volume: 20 | Issue: 11 | Pages: 1556-1557

10.1093/neuonc/noy116 | PMID 30085163 Get It

Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta‐analysis
Hilal, Talal , Almader‐Douglas, Diana , Rosenthal, Allison , Reeder, Craig B. , Jain, Tania , Almader-Douglas, Diana, Rosenthal, Allison , Jain, Tania , Hilal, Talal , Wang, Zhen

Mayo Clinic

American Journal of Hematology | July 23, 2018 | Volume: 93 | Issue: 10 | Pages: 1220-1226

10.1002/ajh.25226 | PMID 30033656 Get It

AbstractMantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta‐analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials from database inception through November 1, 2017. Only full‐text articles were included. Prespecified data elements were extracted from each trial. Outcomes of interest included progression‐free survival (PFS) and overall survival (OS). The overall effect was pooled using the Der Simonian‐Laird random effects model. Three randomized controlled trials and four observational studies met our inclusion criteria and were identified in the analyses. Six studies compared RM therapy to observation, and one compared RM therapy to interferon alfa. Meta‐analysis evaluating outcomes of patients treated after ASCT revealed that RM improved for both PFS (HR = 0.33, 95% CI = 0.23‐0.49) and OS (HR of death = 0.35, 95% CI = 0.17‐0.69). A second meta‐analysis of studies evaluating outcomes of patients who are ASCT‐ineligible treated with anthracycline‐based induction therapy revealed that RM improved PFS (HR = 0.38, 95% CI = 0.25‐0.58). There is a paucity of data on the role of RM in ASCT‐ineligible patients and those with relapsed disease. Overall, RM therapy appears to improve PFS and OS in previously untreated patients with mantle cell lymphoma who undergo induction chemoimmunotherapy followed by ASCT.
Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure
Chen, Harvey S., Joo, Dong Jin , Shaheen, Mohammed F. , Li, Yi , Wang, Yujia , Nicolas, Clara T., Predmore, Kelly, Amiot, Bruce , Michalak, Gregory, Mounajjed, Taofic, Fidler, Jeff L. , Kremers, Walter K. , Nyberg, Scott L. , Shaheen, Mohammed, Fidler, Jeff, Kremers, Walter K , Yang, Jian , Predmore, Kelly S, Fidler, Jeff L.

Mayo Clinic

Hepatology | July 19, 2018 | Volume: 69 | Issue: 1 | Pages: 329-342

10.1002/hep.30184 | PMID 30022502 Get It

Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio‐artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild‐type large white swine (20 kg‐30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24‐48 hours after hepatectomy: Group1—standard medical therapy (SMT, n = 6); Group2—SMT plus bio‐artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3—SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200‐g group survived to 90 hours ( P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200‐g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200‐g group compared with the SMT ( P < 0.01) and 0‐g (P < 0.01) groups. Ki‐67 staining showed increased positive staining at 48 hours following hepatectomy ( P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.
Year in Review in Cardiac Electrophysiology
Park, David , Viswanathan, Mohan , Madhavan, Malini , Ceresnak, Scott R. , Wang, Paul J. , Kapa, Suraj , Park, David S , Davis, Darryl Raymond , Steinberg, Benjamin A. , Tzou, Wendy S.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 16, 2018 | Volume: 11 | Issue: 7 | Pages: No page available

10.1161/circep.118.006648 | PMID 30012874 Get It

Objective but Not Subjective Short Sleep Duration Is Associated With Hypertension in Obstructive Sleep Apnea
Ren, Rong , Covassin, Naima , Yang, Linghui , Zhang, Ye , Zhou, Junying , Tan, Lu, Li, Taomei , Li, Xiao , Wang, Yanyan , Zhang, Jihui , Tang, Xiangdong , Tang, Xiangdong , Li, Yun , Tan, Lu, Wing, Yun Kwok , Li, Weimin , Somers, Virend K.

Mayo Clinic

Hypertension | July 9, 2018 | Volume: 72 | Issue: 3 | Pages: 610-617

10.1161/hypertensionaha.118.11027 | PMID 29987105 Get It

Extremes of sleep duration and obstructive sleep apnea (OSA) are both associated with hypertension. We aimed to explore whether sleep duration modifies the relationship between OSA and prevalent hypertension, using both objective and subjective measures of total sleep duration. A total of 7107 OSA patients and 1118 primary snorers were included in the study. Hypertension was defined based either on direct blood pressure measures or on diagnosis by a physician. Objective sleep duration was derived by polysomnography and subjective sleep duration was self-reported. Logistic regression models were used to estimate the associations between objective/subjective sleep duration and hypertension prevalence in OSA and primary snorers. Compared with primary snorers, OSA combined with objective sleep duration of 5 to 6 hours increased the odds of hypertension by 45% (odds ratio, 1.45; 95% confidence interval, 1.14–1.84), whereas OSA combined with objective sleep duration <5 hours further increased the odds of hypertension by 80% (odds ratio, 1.80; 95% confidence interval, 1.33–2.42). These results were independent of major confounding factors frequently associated with OSA or hypertension. In stratified analysis by sleep duration, risk of hypertension in those with extremely short sleep (<5 hours) was not significantly different between OSA and primary snorers, whereas odds were significant for OSA in the other 4 sleep duration strata (5–6, 6–7, 7–8, and >8 hours). No significance was evident using subjective sleep duration. We conclude that objective short sleep duration is associated with hypertension in OSA patients. Extremely short sleep duration in itself may actually be even more detrimental than OSA in terms of hypertension risk.
Neurosurgery and the rise of academic social media: what neurosurgeons should know
Linzey, Joseph R. , Graffeo, Christopher S. , Wang, Justin Z. , Haider, Ali S. , Alotaibi, Naif M.

Mayo Clinic

Journal of Neurosurgery | July 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.3171/2018.2.jns172817 | PMID 29979122 Get It